UMIN-CTR History

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Unique ID issued by UMIN UMIN000005221
Receipt No. R000006203
Scientific Title A phase II study of pemetrexed plus carboplatin followed by pemetrexed maintenance therapy in chemotherapy-naive elderly patients with non-squamous non-small cell lung cancer
Date of disclosure of the study information 2011/03/09
Last modified on 2019/10/10 09:52:04

No. Disposal Last modified on Item of update
1 Insert 2011/03/09 14:41:09
2 Update 2012/03/09 13:28:59 Post marketing survey by drug manufacture etc., specified by Japanese law.
Institutions
3 Update 2013/04/02 15:35:00 Email
4 Update 2013/09/13 10:51:46 Email
Institutions
5 Update 2013/09/13 10:53:13 Key secondary outcomes
Key secondary outcomes
6 Update 2013/09/13 10:58:40 Key inclusion criteria
Key inclusion criteria
7 Update 2013/09/13 10:59:48 Last follow-up date
8 Update 2014/03/19 11:50:29 Last follow-up date
9 Update 2016/02/25 10:47:40 Name of person sending information
Name of person sending information
Organization
Organization
Division name
Division name
Address
Address
TEL
10 Update 2017/09/19 09:46:37 Last follow-up date
11 Update 2018/03/14 12:46:05 Recruitment status
12 Update 2018/03/14 12:57:20 Organization
Organization
Division name
Division name
Address
Address
TEL
Name of primary sponsor
Organization
13 Update 2019/10/09 10:21:24 Number of participants that the trial has enrolled
Results
14 Update 2019/10/09 10:24:52 Recruitment status
Date of IRB
Last follow-up date
15 Update 2019/10/09 10:32:14 URL releasing protocol
URL related to results and publications
Results
Results date posted
Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures
16 Update 2019/10/09 10:33:03 Results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
17 Update 2019/10/09 10:47:41 Recruitment status
Last follow-up date
18 Update 2019/10/10 09:51:08 URL releasing protocol
Results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
19 Update 2019/10/10 09:52:04 Recruitment status


Contact us.